We previously described the use of extended polymerase chain reaction (PCR) to amplify contiguous 9.2-kilobase (kb) single-long terminal repeat (LTR) proviral sequences from HIV-1 genetic subtypes A through G. We now extend these findings by describing a novel vector system to recover infectious molecular clones from long PCR amplicons. Directional ligation of 9.2-kb proviral amplicons into a recovery vector reconstitutes missing LTR sequences, providing candidate molecular clones for infectivity screening. We show that a previously characterized infectious molecular clone of HIV-1 retains its biological properties upon recovery with this strategy. Three additional infectious molecular clones generated, from primary isolates of subtype B (HIV-1 WR27 ) and circulating recombinant form 01_AE (subtype E) (HIV-1 CM235 ) by subtype-specific LTR reconstitution, displayed biological properties reflecting their cognate parental isolates. This represents the first report of infectious molecular clones from circulating recombinant form 01_AE (subtype E).
INTRODUCTION
Infectious molecular clones of the human immunodeficiency virus type 1 (HIV-1) have been critical tools in the dissection of the basic mechanisms of viral replication and pathogenesis as well as in the extraordinary genetic diversity of HIV-1. They have permitted a systematic evaluation of the biological and immunological characteristics of HIV-1 genes and will be useful in the development of preventive vaccines, as they provide a functional context for viral gene products.
Infectious molecular clones are difficult to recover, given the high proportion of defective viral genomes produced during HIV-1 infection (Li et al., 1991 (Li et al., , 1992 Meyerhans et al., 1989) . Currently available infectious molecular clones have been derived from subtype B strains, either from chronically infected neoplastic T-cell lines or from late-staged patients. These reagents fail to reflect prevalent virus in the pandemic. Early techniques to recover infectious molecular clones of HIV-1 involved genomic library construction in bacteriophage to recover integrated or circularly permuted, nonintegrated proviral forms that could subsequently be restored to infectious form through ligation. Although feasible, these approaches were both laborious and inefficient. The advent of the polymerase chain reaction (PCR) and discovery of thermal stable DNA polymerases (Saiki et al., 1985 (Saiki et al., , 1988 allowed for the amplification of multiple, 4-to 5-kilobase (kb), subgenomic proviral sequences that could be reconstituted into full-length proviruses (Gibbs et al., 1994) . This approach, however, was highly susceptible to the production of mosaic proviral genomes.
The addition of thermal stable DNA polymerases with 3Ј to 5Ј exonucleotidyl repair activities and modified salt conditions allowed for the amplification of very long DNA targets (Barnes, 1994; Cheng et al., 1994) . Terminally redundant LTR sequences in HIV-1 prohibit PCR-mediated recovery of complete proviral genomes. Thus, our previously described approach to recover virtually fulllength HIV-1 proviral sequences as a single, contiguous 9.2-kb DNA fragment from all known genotypes (Salminen et al., 1995b) yielded proviral amplicons with incomplete LTR sequences. Although this provided a powerful tool for the study of global HIV-1 subtype evolution and recombination (Carr et al., 1996; Salminen et al., 1995a Salminen et al., , 1996 , the amplified proviruses were not recovered in an infectious form. We now describe a system affording the recovery of infectious molecular clones of primary isolates of HIV-1 from subtype B and circulating recombinant form (CRF)01_AE (subtype E) (Robertson et al., 2000) by reconstitution of the missing LTR sequences, in which the biological properties of these reagents reflect those of their cognate parental isolates.
RESULTS

Infectious molecular clone recovery strategy
We developed a combined PCR amplification and molecular cloning vector strategy, which allows for the amplification and direct cloning of HIV-1 proviral sequences to produce an infectious molecular clone. Virtually fulllength provirus is amplified as a single, contiguous 9.2-kb DNA fragment, beginning at the junction of the 5Ј LTR and gag leader sequence and extending to the R/U5 region junction of the 3Ј LTR. Primers used for the amplification generate the restriction enzyme recognition sequences for BbeI and BglI at the 5Ј and 3Ј ends, respectively, of the fragment. Both sites are otherwise absent from the genomes of all previously described full-length HIV-1 proviruses. Because of the absence of LTR sequences, the amplicon is incapable of producing infectious virus upon transfection into susceptible cells. We developed vectors to replace the missing LTR sequences from both subtype B and CRF01_AE (subtype E) HIV-1 (pLTR(B)1/2⌬, and pLTR(E)1/2⌬, respectively (Fig.  1) . pLTR(B)1/2⌬ and pLTR(E)1/2⌬ contain LTR sequences from the infectious molecular clone pNL4-3 and the isolate HIV-1 CM235 , respectively (see Material and Methods). Upon BbeI, BglI directional cloning of the proviral amplicon into these vectors, the genomic organization of the entire provirus is precisely regenerated and is potentially infectious.
Recovery of infectious molecular clones
To test the validity of the strategy, we amplified and cloned proviral sequences from the reference subtype B infectious molecular pNL4-3, initially derived from bacteriophage library screening. We also recovered proviral sequences from HIV-1 WR27 , a subtype B R5X4 isolate, and HIV-1 CM235 , a CRF01_AE (subtype E) R5 isolate, to test whether the method could be used to generate infectious molecular clones from primary viruses. HIV-1 CM235 was chosen, as this strain is representative of HIV-1 prevalent in Thailand (Carr et al., 1996) , where large-scale, preventive vaccine efficacy trials are planned. We were able to generate infectious molecular clones from the reference clone and both of the primary isolates. Virtually fulllength HIV-1 WR27 and HIV-1 CM235 proviruses were ligated into pLTR(B)1/2⌬ and pLTR(E)1/2⌬, respectively, to provide subtype-specific LTR reconstitution.
During the recovery of infectious clones from HIV-1 WR27 , 48 of 6 ϫ 10 3 bacterial colonies were positive upon initial hybridization screening, 26 of these contained fulllength proviral inserts, and 11 of 15 clones tested produced p24 antigen following transfection into COS-1 cells. Only one of these 11 stocks (pWR27-1) was capable of infecting PHA/IL-2-stimulated, seronegative donor peripheral blood mononuclear cells (PBMC). Two molecular clones derived from HIV-1 CM235 , capable of spreading infection in PBMC, were also obtained in this fashion (with similarly low stepwise yields) and were designated pCM235-2 and pCM235-4. Complete genome sequencing of the three infectious molecular clones derived from primary isolates revealed an absence of gross deletions, nonsense mutations, or evidence for genetic rearrangement.
Attempts to recover an infectious molecular clone of HIV-1 WR27 from a bacteriophage library resulted in a single molecular clone that failed to propagate in subsequent PBMC infections.
Biological characterization of infectious molecular clones
We compared the biological properties of the original pNL4-3 bacteriophage -derived infectious molecular clone with its cognate reamplified and restored pL-TR(B)1/2⌬-derived clone. The biological properties of the primary isolate WR27 were compared to those of the pWR27-1 infectious molecular clone produced by PCR. To compare viral replication kinetics, we transfected molecular clones into COS-1 cells to produce initial inoculum viral stocks, and then used these to infect PHA/IL-2-stimulated PBMC to generate short-term passage viral stocks. A PBMC stock was similarly prepared from the HIV-1 WR27 isolate. All viral stocks were titered on PBMC derived from the same donor leukopack. Figure 2 shows the results of p24 antigen production from PBMC infected with 100 TCID 50 of each virus stock. As shown in Fig. 2a , comparison of the parental HIV-1 NL4-3 bacteriophage -derived virus and the PCR-generated infectious clone derived from it revealed equivalent replication kinetics. The MT-2 cell-derived biological phenotype and coreceptor utilization profiles were also maintained (Table 1).
There was no appreciable difference between the PBMC replication kinetics of either the parental HIV-1 WR27 isolate or the cognate infectious molecular clone pWR27-1 (Fig. 2b ). pWR27-1 also retained the SI phenotype of the parental isolate and exclusively utilized CXCR4; the parental HIV-1 WR27 isolate predominately utilized CXCR4, indicating that a representative clone was recovered from the quasi-species (Table 1) . Both pCM235-2 and pCM235-4 replicated equivalently in PBMC compared with parental HIV-1 CM235 (Fig. 2c) , were NSI, and exclusively used CCR5 (Table 1) .
We next examined the replication kinetics of the infectious molecular clones in primary human macrophages. As expected, both the parental and PCR-derived HIV-1 NL4-3 infectious molecular clones failed to replicate in macrophages (Table 1) . Minimal replication in macrophages (peak p24 antigen level Ͻ 1000 pg/ml) was observed for both HIV-1 WR27 and pWR27-1 (Table 1) . Both pCM235-2 and pCM235-4, despite being NSI and showing exclusive CCR5 utilization, failed to replicate in primary macrophages, as was previously noted by our group for HIV-1 CM235 (J. R. Mascola, unpublished observations). The observations are consistent with recent data showing that biological phenotype and coreceptor utilization assays imperfectly predict efficient replication in primary macrophages (Cheng-Mayer et al., 1997; Chesebro et al., 1996; Dittmar et al., 1997; Smyth et al., 1998) and that envelope-dependent, postentry activation of primary macrophages may influence tropism (Arthos et al., 2000) .
The MT-2 phenotype, coreceptor preference, and macrophage replication kinetics of five control viruses, HIV-1 MN , HIV-1 BaL , HIV-1 JR-FL , HIV-1 JR-CSF , and HIV-1 ADA-M , were consonant with their predicted properties. HIV-1 MN was SI phenotype, exclusively used CXCR4, and failed to replicate in primary macrophages, while the remaining four viruses were NSI, exclusively used CCR5, and were capable of macrophage replication (Table 1) .
DISCUSSION
Molecular virologic and phylogenetic studies of fulllength HIV-1 genomes have largely been conducted using infectious molecular clones derived from screening of bacteriophage libraries. We now show that an alternative approach, using PCR amplification of virtually fulllength proviruses followed by molecular cloning into an LTR reconstitution vector, can generate infectious molec- ular clones of HIV-1 from primary isolates, which reflect the biological properties of the parental isolate.
This cloning strategy initially results in heterologous 5Ј LTR and 3Ј U5 sequences. Following initial transfection and reinfection, however, all but 31 bp of the distal R and the complete 83-bp U5 region are replaced by autologous LTR sequences during reverse transcription. These heterologous sequences could be replaced with autologous sequences by standard molecular biological techniques, when critical to an experimental design. Although the primers used in the provirus amplification were previously found to amplify subtypes A through G (Salminen et al., 1995b) , the LTR reconstitution vectors described here were optimized for subtypes B and E proviruses. During reverse transcription, strong-stop DNA containing R, U5, and primer binding site sequences with minus-strand orientation jump to the 3Ј LTR, where efficient hybridization between strong-stop and viral RNA 3Ј R region sequences must occur. R region incompatibilities in an inter-subtype RNA-DNA heteroduplex could interfere with efficient viral replication. Preliminary data in our laboratory suggest that this does occur when attempting to recover PCR amplicons of HIV-1 CRF01_AE (subtype E) into pLTR(B)1/2⌬ (subtype B) (unpublished data). However, generation of pL-TR(B/E)1/2⌬ analogs from different subtypes should permit the efficient recovery of infectious molecular clones from any HIV-1 subtype.
The future applications of the approach described here are myriad. We are in the process of developing a panel of infectious molecular clones from all described HIV-1 subtypes for the delineation of subtype-specific replication kinetics, transcriptional regulation, coreceptor utilization, and inter-subtype recombination events.
These infectious molecular clones will provide a standardized panel of reagents both to develop novel vaccine immunogens and to test host cellular immune responses to them in preclinical and clinical trials. An infectious molecular clone of HIV-1 subtype D was recently recovered in our laboratory, confirmed by whole-genome sequencing, and is now being biologically characterized (data not shown).
Finally, the availability of completely characterized, quality-controlled, permanent seed stocks of HIV-1 viruses of different subtypes will provide an essential, long-term resource for all aspects of HIV diagnostics, therapy, and prevention. Such a panel is readily attainable based on the results reported herein.
MATERIALS AND METHODS
HIV-1 parental molecular clones and isolates
HIV-1 infectious molecular clone pNL4-3 was obtained from the NIAID AIDS Research and Reference Reagent Program. The plasmid was propagated in E. coli strain DH5␣ and purified for transfection and PCR experiments using Qiagen columns (Qiagen, Chatsworth, CA). pNL4-3 is an infectious molecular clone of the T-cell-lineadapted virus HIV-1 NL4-3 , which uses the coreceptor CXCR4 and induces syncytia (syncytium-inducing, SI phenotype) in MT-2 cells (Adachi et al., 1986) . HIV-1 NL4-3 belongs to HIV-1 group M, subtype B, and its biological properties were previously characterized (Adachi et al., 1986) . HIV-1 subtype B isolate WR27 (HIV-1 WR27 ) was obtained in 1988 by short-term coculture of peripheral blood mononuclear cells (PBMC) from a subject with Walter Reed Stage 5, symptomatic HIV-1 infection as described previously (Salminen et al., 1995b) and HIV-1 CRF01_AE (subtype E) isolate CM235 (HIV-1 CM235 ) was obtained from an early-stage HIV-1-infected individual in northern Thailand (McCutchan et al., 1992) .
Polymerase chain reaction
Virtually complete provirus was amplified from DNA extracted at the peak of p24 antigen production from infected PBMC or from the original infectious molecular clone in the case of pNL4-3. Primers MSF12 (AAA-TCTCTAGCAGTGGCGCCCGAACAG) and MSR5 (ACGTGCcCTCAAGGCAAGCTTTATTGAGGCT) were used to amplify the provirus as previously described (Salminen et al., 1995b) . Note that primer MSR5 was modified from MSR5 (Salminen et al., 1995b) to include a 4-bp 5Ј-clamp sequence followed by A to C mutation at position 7 (lowercase) to generate a BglI restriction enzyme site (underlined). Primer MSF12 contains a natural BbeI/NarI site (underlined). Both sites are GC rich and do not occur at other positions in the HIV-1 genome among all described complete HIV-1 genomes.
Preparation of vector plasmid backbone
Construction of the LTR reconstitution vectors pL-TR(B)1/2⌬ and pLTR(E)1/2⌬ was based on the 3.4-kb plasmid pBC KSϩ (Stratagene, La Jolla, CA), which carries the chloramphenicol acetyl transferase (CAT) gene as well as a polylinker sequence. A unique BglI site in pBC KSϩ was removed by digestion with restriction enzymes NaeI and PvuI, followed by blunting and religation of the ends. The resulting plasmid was digested with XbaI and EcoRI and linear forms were recovered by gel purification.
Preparation of LTR-cloning cassette
LTR sequences of HIV-1 were PCR amplified from the infectious molecular clone pNL4-3 or from genomic DNA isolated from PBMC infected with HIV-1 CM235 . The LTR-cassette assembly strategy was the same for both NL4-3 and CM235. Primer sequences and restriction sites differ, to reflect template sequence differences. For NL4-3 a 661-bp complete 5Ј-LTR (LTR1, Fig. 1 ) was amplified using primers MSF13 (GGCTAGTCTAGATGGAAGGGCTAATTTGGTC-CCAAA) and MSR7 (GCATGCGGATCCGTTCGGGCGCCACT-GCTAGAGATT); the 116-bp 3Ј-U5 region (LTR2⌬) was amplified using primers MSF15 (GCATGCGGATCCGCCTTGAGgGCTACAAGTAGTGTG) and MSR8 (GCATGCGAATTC-CTGCTAGAGATTTTCCACACTGA). These primers contained restriction enzyme recognition sites XbaI, BamHI, BamHI, and EcoRI, respectively (underlined) . For CM235 cognate PCR fragments of 670 and 122 bp (Fig. 1) were amplified using primers E-f13 (GCATGCCCTAGGTGGAWGGGC-TARTTYACTCCAAGA) and E-r7 (GCATGCGGATCCGT-TCGGGCGCCACTGCTAGAGATT); and E-f15 (GCATGCGGATCCGCCTTGAGgGCTTAAAGTGGTGTG) and E-r8 (GCATGCGAATTCCTGCTAGAGATTTTTACTCAGT), respectively. These primers contained restriction enzyme recognition sites AvrII, BamHI, BamHI, and EcoRI, respectively (underlined) . MSF15 and E-f15 primer sequences reflect a one-base transversion (T 3 G, lowercase), which introduces a unique BglI restriction enzyme recognition site at the junction between the R and U5 regions. MSR7 and E-r7 each contain a natural BbeI site (boldface).
The amplified LTR fragments were cloned into vector pCR-II (Invitrogen, San Diego, CA) and sequenced using a Model 377 DNA sequencer (Applied Biosystems, Foster City, CA). NL4-3 LTR1 and LTR2⌬ clones that agreed with the published LTR sequences from pNL4-3 (GenBank accession number M19921) were selected and double-digested with XbaI plus BamHI, and BamHI plus EcoRI restriction enzyme combinations, respectively, to release the LTR fragments. Sequences from HIV-1 CM235 LTR clones were found to be virtually identical to those from the highly related strain HIV-1 CM240 (GenBank accession number U54771). Individual clones of HIV-1 CM235 5Ј LTR sequences were selected, based on their ability to support basal and Tat-enhanced transcription using previously described assays (Michael et al., 1994) . CM235 LTR1 and LTR2⌬ clones were derived from those enabling the best transcription and double-digested with AvrII plus BamHI, and BamHI plus EcoRI, respectively. Homologous digested LTR products were gel purified and ligated at the BamHI site to join the two LTR fragments in a cassette containing one 5Ј-LTR1 and one 3Ј-LTR2⌬. Fragments of the correct size were gel purified and ligated to the previously prepared pBC-KSϩ XbaI plus EcoRI-digested plasmid backbone, and the transformants were screened for the proper insert. The AvrII and XbaI sites are ligation compatible with resultant loss of both sites. The final constructions, pLTR(B)1/2⌬ and pLTR(E)1/2⌬ derived from HIV-1 NL4-3 and HIV-1 CM235 , respectively, were confirmed by DNA sequencing. Thus, HIV-1 provirus amplified with primers MSF12 and MSR5 can be directionally inserted into these vectors by means of the unique restriction enzyme sites BglI and BbeI (or NarI) to regenerate potentially infectious molecular clones of HIV-1.
Molecular cloning of full-length HIV-1 provirus
To directly clone amplified HIV-1 provirus into the pLTR(B)1/2⌬ and pLTR(E)1/2⌬ vectors, MSF12/MSR5-amplified PCR products were pooled, extracted with phenol:chloroform:isoamyl alcohol (25:24:1), ethanol precipitated, and resuspended in sterile, deionized water. A 1-g sample of the fragment was first digested in BbeI buffer with 5 to 10 units of BbeI (Panvera, Madison, WI) for 5 to 8 h at 37°C in a total volume of 10 l. Next, 0.7 l of 10ϫ concentrated BglI reaction buffer and 5 to 10 units of BglI (New England Biolabs, Beverly, MA) were added and the fragment was digested overnight at 37°C in a total volume of 12 l. pLTR(B)1/2⌬ and pLTR(E)1/2⌬ were digested with BbeI and BglI in a similar fashion. The digestion products were organic-extracted, gel purified with the QiaQuick technique (Qiagen), ligated together, electroporated into E. coli DH5␣ cells, and recovered on Luria-Bertani medium (LB) plates containing 20 g/ml of chloramphenicol (Sigma, St. Louis, MO) at 32°C. Transformants were picked into individual wells of sterile 96-well plates containing 200 l of LB supplemented with 20 g/ml of chloramphenicol, grown overnight at 32°C, and replica plated onto 137-mm-diameter nitrocellulose filters (Protran; Schleicher & Schuell, Keene, NH) overlying 150-mm-diameter LB-chloramphenicol plates. After overnight growth at 32°C, the filters were denatured, neutralized, washed, and UV-crosslinked as previously described (Artenstein et al., 1995) . Dried filters were screened for correct inserts using a [
32 P] random primerlabeled probe (NL4-3 9.2-kb fragment bounded by MSF12/MSR5). Bacteria from positive wells were streaked out onto fresh LB-chloramphenicol plates and the resulting colonies were screened for the proper vector and insert sequences by restriction enzyme digestion.
Bacteriophage cloning
Seronegative donor PBMC, depleted of CD8ϩ cells by adherence to a flask coated with a CD8 monoclonal antibody (MicroCELLector; Applied Immune Sciences, Santa Clara, CA), were acutely infected with a cell-free stock of the primary isolate WR27. Cells were harvested at the peak of p24 antigen production and high-molecular-weight DNA was prepared by spooling. Following partial digestion with Sau3A to generate an average insert size of 15-kb pairs, a genomic library was prepared in Lambda Fix-it II (Stratagene) and 2 ϫ 10 6 plaques were screened with a full-length HIV probe.
Recovery of viral stocks
Samples of LTR-reconstituted proviral clones (20-25 g) were transfected into 1.5 ϫ 10 7 COS-1 cells by electroporation (0.22 kV, 960 F). The COS-1 cells were then maintained in a humidified, 5% CO 2 environment at 37°C for 48 h posttransfection in DMEM supplemented with 10% fetal calf serum (PAA Laboratories, Newport Beach, CA), 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine. Supernatants were saved and 3 ml of fresh medium was added to each well for an additional 24 h. At 72 h posttransfection supernatant fluids were then cleared by centrifugation at 300 g, filtered through 0.22-M syringe filters (Millipore, Bedford, MA), and monitored for p24 antigen production by the Coulter assay (Coulter, Hialeah, FL). p24 antigen-positive supernatants, typically in the 0.3 to Ն20 ng/ml range, were subsequently tested for infectivity.
Peripheral blood mononuclear cell growth kinetics PHA/IL-2-stimulated seronegative donor PBMC (2 ϫ 10 6 ) were exposed to 1 ml of p24 antigen-positive COS-1 cell supernatant. After overnight infection, cells were washed and maintained in culture media (RPMI 1640 supplemented with 15% fetal calf serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine) containing 20 U/ml human recombinant IL-2. Virus replication was monitored by p24 antigen production and culture supernatant harvested at peak p24 antigen production was used to measure virus tissue culture infectious dose 50 (TCID 50 ). To measure virus growth kinetics, triplicate wells of a 96-well microtiter plate, containing 1.5 ϫ 10 5 PHA/IL-2-stimulated PBMC per well, were infected overnight with ϳ100 TCID 50 of each virus stock. Cells were washed and maintained in IL-2-supplemented culture media. One-half of the culture supernatant was harvested and replaced every 2 to 3 days for 20 days. Culture supernatant from triplicate wells was pooled and p24 antigen was measured in batch at the end of the assay.
Macrophage replication kinetics
Macrophages were prepared from PBMC of HIV-1 seronegative donors by overnight adherence to plastic flasks precoated with heat-inactivated normal human serum (NHS). Nonadherent cells were removed by vigorous washing with culture media and macrophages were detached using cold Ca 2ϩ -and Mg 2ϩ -free phosphate-buffered saline (PBS) as described (Gartner et al., 1986) . Macrophages were then seeded at 1 ϫ 10 5 cells per well in flat-bottomed 96-well microtiter plates and maintained in culture media supplemented with 10% NHS for 7 days prior to infection. To evaluate virus growth kinetics, cells in triplicate wells were exposed overnight to ϳ400 TCID 50 of virus stock and washed thoroughly, and culture supernatant p24 antigen was monitored every 3 to 4 days for 4 weeks. Culture supernatant from triplicate wells was pooled and p24 antigen was measured in batch at the end of the assay. Control macrophage-tropic (BaL, JR-CSF, JR-FL, ADA-M) and Tcell-line-adapted viruses (MN) were obtained from the NIAID AIDS Research and Reference Reagent Program and propagated in PHA/IL-2-stimulated PBMC.
MT-2 phenotyping assay
The ability of the PBMC-derived viruses to induce syncytia in MT-2 cells was evaluated using the AIDS Clinical Trials Group consensus protocol (Japour et al., 1994) . MT-2 cells were exposed to 200 TCID 50 of each virus in duplicate wells. Viruses were assigned the SI phenotype if Նthree syncytia per low-powered field (100ϫ) were observed during a 21-day observation period.
HIV-1 entry coreceptor usage
Coreceptor usage was evaluated using human osteoblastic sarcoma (HOS) cells transduced with CD4, CD4 plus CCR5, or CD4 plus CXCR4 as previously described (Michael et al., 1997) for all viruses except HIV-1 CM235 , where typing was done using a modification of the GHOST cell assay (Michael et al., 1998) . The percentage GFP-positive cells in mock-infected GHOST cells was subtracted from that of viral-infected GHOST cells. The percentage GFP-positive infected parental cells was then subtracted from that of all other receptor-transduced GHOST cell infections to control for low-level, endogenous CXCR4 expression. Finally, these corrected percentages of GFP-positive cells were normalized for relative cell line GFP production, reflected by parallel infections with MLV-E pseudotyped HIV-1 (which enter GHOST cells independently of CD4 or coreceptor utilization), by multiplication by the ratio (mean GHOST MLV-E percentage GFP positives/coreceptor specific MLV-E percentage GFP positives).
Full-length proviral sequencing
Infectious molecular clones of HIV-1 NL4-3 , HIV-1 WR27 , HIV-1 CM235-2 , and HIV-1 CM235-4 were sequenced on a Model 377 Applied Biosystems automated sequencer; contigs representing complete sequencing on both strands were assembled using Sequencher version 3.1 software (Gene Codes Corporation, Ann Arbor, MI); and consensus sequences were submitted to GenBank for each. HIV-1 NL4-3 and HIV-1 WR27 are deposited with accession numbers U26942 and AF286365, respectively; HIV-1 CM235-2 and HIV-1 CM235-4 were deposited with accession numbers AF259954 and AF259955, respectively. New sequences were compared to reference sequences using the MegAlign program contained within the DNAStar package (DNAStar, Madison, WI).
